Literature DB >> 16249455

Susceptibility to diabetic nephropathy is related to dicarbonyl and oxidative stress.

Paul J Beisswenger1, Keith S Drummond, Robert G Nelson, Scott K Howell, Benjamin S Szwergold, Michael Mauer.   

Abstract

Dicarbonyl and oxidative stress may play important roles in the development of diabetes complications, and their response to hyperglycemia could determine individual susceptibility to diabetic nephropathy. This study examines the relationship of methylglyoxal, 3-deoxyglucosone (3DG), and oxidative stress levels to diabetic nephropathy risk in three populations with diabetes. All subjects in the Overt Nephropathy Progressor/Nonprogressor (ONPN) cohort (n = 14), the Natural History of Diabetic Nephropathy study (NHS) cohort (n = 110), and the Pima Indian cohort (n = 45) were evaluated for clinical nephropathy, while renal structural measures of fractional mesangial volume [Vv(Mes/glom)] and glomerular basement membrane (GBM) width were determined by electron microscopy morphometry in the NHS and Pima Indian cohorts. Methylglyoxal and 3DG levels reflected dicarbonyl stress, while reduced glutathione (GSH) and urine 8-isoprostane (8-IP) measured oxidative stress. Cross-sectional measures of methylglyoxal production by red blood cells incubated in 30 mmol/l glucose were increased in nephropathy progressors relative to nonprogressors in the ONPN (P = 0.027) and also reflected 5-year GBM thickening in the NHS cohort (P = 0.04). As nephropathy progressed in the NHS cohort, in vivo levels of methylglyoxal (P = 0.036), 3DG (P = 0.004), and oxidative stress (8-IP, P = 0.007 and GSH, P = 0.005) were seen, while increased methylglyoxal levels occurred as nephropathy progressed (P = 0.0016) in the type 2 Pima Indian cohort. Decreased glyceraldehyde-3-phosphate dehydrogenase activity also correlated with increased methylglyoxal levels (P = 0.003) in the NHS cohort. In conclusion, progression of diabetic nephropathy is significantly related to elevated dicarbonyl stress and possibly related to oxidative stress in three separate populations, suggesting that these factors play a role in determining individual susceptibility.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16249455     DOI: 10.2337/diabetes.54.11.3274

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  56 in total

Review 1.  Role of advanced glycation endproducts and glyoxalase I in diabetic peripheral sensory neuropathy.

Authors:  Megan Jack; Douglas Wright
Journal:  Transl Res       Date:  2012-01-10       Impact factor: 7.012

2.  Bisphosphonate treatment of type I diabetic mice prevents early bone loss but accentuates suppression of bone formation.

Authors:  Lindsay M Coe; Srinivasan Arjun Tekalur; Yutian Shu; Melissa J Baumann; Laura R McCabe
Journal:  J Cell Physiol       Date:  2015-08       Impact factor: 6.384

3.  Site specific modification of the human plasma proteome by methylglyoxal.

Authors:  Michael J Kimzey; Owen R Kinsky; Hussein N Yassine; George Tsaprailis; Craig S Stump; Terrence J Monks; Serrine S Lau
Journal:  Toxicol Appl Pharmacol       Date:  2015-10-03       Impact factor: 4.219

Review 4.  Role of Kidney Biopsies for Biomarker Discovery in Diabetic Kidney Disease.

Authors:  Helen C Looker; Michael Mauer; Robert G Nelson
Journal:  Adv Chronic Kidney Dis       Date:  2018-03       Impact factor: 3.620

5.  Glucose autoxidation induces functional damage to proteins via modification of critical arginine residues.

Authors:  Sergei Chetyrkin; Missy Mathis; Vadim Pedchenko; Otto A Sanchez; W Hayes McDonald; David L Hachey; Hartman Madu; Donald Stec; Billy Hudson; Paul Voziyan
Journal:  Biochemistry       Date:  2011-06-20       Impact factor: 3.162

Review 6.  The natural progression of kidney injury in young type 1 diabetic patients.

Authors:  Julia M Steinke
Journal:  Curr Diab Rep       Date:  2009-12       Impact factor: 4.810

7.  Poly(ADP-ribose) polymerase (PARP) inhibition counteracts multiple manifestations of kidney disease in long-term streptozotocin-diabetic rat model.

Authors:  Hanna Shevalye; Roman Stavniichuk; Weizheng Xu; Jie Zhang; Sergey Lupachyk; Yury Maksimchyk; Viktor R Drel; Elizabeth Z Floyd; Barbara Slusher; Irina G Obrosova
Journal:  Biochem Pharmacol       Date:  2009-11-27       Impact factor: 5.858

8.  In vivo and in vitro effects of SREBP-1 on diabetic renal tubular lipid accumulation and RNAi-mediated gene silencing study.

Authors:  Hao Jun; Zhao Song; Wang Chen; Rong Zanhua; Shi Yonghong; Liu Shuxia; Duan Huijun
Journal:  Histochem Cell Biol       Date:  2008-12-02       Impact factor: 4.304

9.  Metformin Scavenges Methylglyoxal To Form a Novel Imidazolinone Metabolite in Humans.

Authors:  Owen R Kinsky; Tiffanie L Hargraves; Tarun Anumol; Neil E Jacobsen; Jixun Dai; Shane A Snyder; Terrence J Monks; Serrine S Lau
Journal:  Chem Res Toxicol       Date:  2016-01-27       Impact factor: 3.739

10.  Hepatocyte nuclear factor 1 and hypertensive nephropathy.

Authors:  Renata I Dmitrieva; Cruz A Hinojos; Eric Boerwinkle; Michael C Braun; Myriam Fornage; Peter A Doris
Journal:  Hypertension       Date:  2008-04-28       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.